JP6190723B2 - 抗ngf組成物およびその使用 - Google Patents
抗ngf組成物およびその使用 Download PDFInfo
- Publication number
- JP6190723B2 JP6190723B2 JP2013542189A JP2013542189A JP6190723B2 JP 6190723 B2 JP6190723 B2 JP 6190723B2 JP 2013542189 A JP2013542189 A JP 2013542189A JP 2013542189 A JP2013542189 A JP 2013542189A JP 6190723 B2 JP6190723 B2 JP 6190723B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- pain
- ngf
- chain polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41883210P | 2010-12-01 | 2010-12-01 | |
| US61/418,832 | 2010-12-01 | ||
| PCT/US2011/062963 WO2012075340A2 (en) | 2010-12-01 | 2011-12-01 | Anti-ngf compositions and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016251053A Division JP2017079779A (ja) | 2010-12-01 | 2016-12-26 | 抗ngf組成物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014507116A JP2014507116A (ja) | 2014-03-27 |
| JP2014507116A5 JP2014507116A5 (cg-RX-API-DMAC10.html) | 2015-01-22 |
| JP6190723B2 true JP6190723B2 (ja) | 2017-08-30 |
Family
ID=46162451
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013542189A Expired - Fee Related JP6190723B2 (ja) | 2010-12-01 | 2011-12-01 | 抗ngf組成物およびその使用 |
| JP2016251053A Abandoned JP2017079779A (ja) | 2010-12-01 | 2016-12-26 | 抗ngf組成物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016251053A Abandoned JP2017079779A (ja) | 2010-12-01 | 2016-12-26 | 抗ngf組成物およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (7) | US9783601B2 (cg-RX-API-DMAC10.html) |
| EP (2) | EP2646468B1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP6190723B2 (cg-RX-API-DMAC10.html) |
| KR (2) | KR102025848B1 (cg-RX-API-DMAC10.html) |
| CN (1) | CN103619879A (cg-RX-API-DMAC10.html) |
| AU (2) | AU2011336470B8 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2821515A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX359070B (cg-RX-API-DMAC10.html) |
| NZ (1) | NZ611076A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2012075340A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1575517T3 (da) | 2002-12-24 | 2012-05-14 | Rinat Neuroscience Corp | Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme |
| US9498530B2 (en) * | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
| SI2350075T1 (sl) | 2008-09-22 | 2014-06-30 | Array Biopharma, Inc. | Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji |
| CN102264736B (zh) | 2008-10-22 | 2013-08-14 | 阵列生物制药公司 | 作为TRK激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物 |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| BR122019024201B1 (pt) | 2010-05-20 | 2021-08-03 | Array Biopharma Inc | Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9783601B2 (en) | 2010-12-01 | 2017-10-10 | Alderbio Holdings Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| CN110408644A (zh) | 2011-05-20 | 2019-11-05 | 奥尔德生物控股有限责任公司 | 多亚基蛋白质例如抗体在转化的微生物例如巴斯德毕赤酵母中的高纯度产生 |
| US10150968B2 (en) | 2011-08-19 | 2018-12-11 | Alderbio Holdings Llc | Multi-copy strategy for high-titer and high-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9062104B2 (en) * | 2013-03-14 | 2015-06-23 | Alderbio Holdings Llc | Therapeutic use of antibodies to HGF |
| US9732150B2 (en) * | 2013-03-14 | 2017-08-15 | Alderbio Holdings Llc | Therapeutic use of antibodies to HGF |
| PL3092251T3 (pl) * | 2014-01-06 | 2021-08-02 | F. Hoffmann-La Roche Ag | Jednowartościowe moduły transportera wahadłowego przez barierę krew-mózg |
| TWI746426B (zh) | 2014-11-16 | 2021-11-21 | 美商亞雷生物製藥股份有限公司 | (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型 |
| MA41097A (fr) * | 2014-12-05 | 2017-10-10 | Glenmark Pharmaceuticals Sa | Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses |
| CA2983030A1 (en) | 2015-04-16 | 2016-10-20 | Alder Biopharmaceuticals, Inc. | Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia |
| AU2016282334B2 (en) | 2015-06-24 | 2022-07-21 | F. Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| MX2018003822A (es) | 2015-10-02 | 2018-06-22 | Hoffmann La Roche | Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso. |
| EP3368039A1 (en) | 2015-10-26 | 2018-09-05 | The Regents of The University of Colorado, A Body Corporate | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| CN109071678B (zh) * | 2016-03-18 | 2022-05-20 | 舒泰神(北京)生物制药股份有限公司 | 神经生长因子融合蛋白、制备方法及其用途 |
| UA125026C2 (uk) | 2016-04-04 | 2021-12-29 | Локсо Онколоджі, Інк. | РІДКІ КОМПОЗИЦІЇ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)ПІРАЗОЛО[1,5-a]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ |
| UA125025C2 (uk) | 2016-04-04 | 2021-12-29 | Локсо Онколоджі, Інк. | Способи лікування дитячих ракових захворювань |
| SG10202109691UA (en) | 2016-04-15 | 2021-10-28 | Alder Biopharmaceuticals Inc | Anti-pacap antibodies and uses thereof |
| MX392604B (es) | 2016-05-18 | 2025-03-24 | Array Biopharma Inc | Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo. |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| CA3067835A1 (en) * | 2017-06-22 | 2018-12-27 | Apexigen, Inc. | Anti-vista antibodies and methods of use |
| WO2019005637A2 (en) * | 2017-06-25 | 2019-01-03 | Systimmune, Inc. | MULTIPECIFIC ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF |
| TW201904588A (zh) * | 2017-06-25 | 2019-02-01 | 美商西雅圖免疫公司 | 引導及導航控制蛋白質之製造及使用方法 |
| WO2019060869A1 (en) * | 2017-09-25 | 2019-03-28 | Discitisdx, Inc. | METHODS FOR TREATING DEGENERATIVE DISC DISEASE AND CHRONIC LOMBALGIA |
| CN109929035B (zh) * | 2017-12-15 | 2022-06-28 | 安源医药科技(上海)有限公司 | 抗人ngf抗体及其制备方法和用途 |
| AR114110A1 (es) | 2018-02-28 | 2020-07-22 | Lilly Co Eli | Anticuerpo anti-trka |
| WO2019178516A1 (en) | 2018-03-16 | 2019-09-19 | SEN-JAM Pharmaceutical LLC | Methods and compositions to treat enteropathic arthritis |
| EP3773621A4 (en) * | 2018-03-27 | 2022-03-23 | Systimmune, Inc. | GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHODS FOR THEIR MANUFACTURE AND USE |
| CN108623687A (zh) * | 2018-04-17 | 2018-10-09 | 中山康方生物医药有限公司 | 神经生长因子的单克隆抗体及其编码基因和应用 |
| CN113924315B (zh) * | 2019-06-10 | 2022-06-28 | 山东博安生物技术股份有限公司 | 抗β-NGF纳米抗体及其应用 |
| CN117186219B (zh) * | 2020-04-17 | 2024-07-12 | 珠海泰诺麦博制药股份有限公司 | 抗人神经生长因子的抗体 |
| CN116003590A (zh) * | 2020-08-06 | 2023-04-25 | 熙源安健医药(上海)有限公司 | 抗ngf抗体及其抗原结合片段、其制备方法和应用 |
| CA3196055A1 (en) * | 2020-09-28 | 2022-03-31 | Navrogen, Inc. | Composition and use of alternatively formatted anti-mesothelin antibodies for the treatment of cancer |
| CN116406368A (zh) * | 2020-10-07 | 2023-07-07 | 赖利制药公司 | 昔布类衍生的缀合化合物及其使用方法 |
| CN115433278A (zh) * | 2021-06-05 | 2022-12-06 | 苏州缔码生物科技有限公司 | 结合cs1蛋白兔重组单克隆抗体及应用 |
| AU2023365813A1 (en) * | 2022-10-18 | 2025-05-22 | Oncoresponse, Inc. | Lilrb2 antibody products and methods |
| IL324457A (en) * | 2023-05-12 | 2026-01-01 | Genmab As | Antibodies capable of binding to ox40, their variants and uses thereof |
| WO2024243049A2 (en) * | 2023-05-19 | 2024-11-28 | Ltz Therapeutics Inc. | Antibodies and uses thereof |
| CN118440185B (zh) * | 2024-05-22 | 2024-11-19 | 宁夏大学 | 抗bhv-1的重组兔单克隆抗体及双抗体夹心elisa试剂和应用 |
| CN118465261B (zh) * | 2024-07-09 | 2024-10-15 | 浙江康佰裕生物科技有限公司 | 一种检测逆转录病毒载体物理滴度的elisa试剂盒 |
| CN118702814B (zh) * | 2024-07-12 | 2026-03-06 | 麦里生物科技(上海)有限公司 | 一种抗ngf单克隆抗体及其应用 |
Family Cites Families (353)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4230691A (en) | 1978-05-23 | 1980-10-28 | The Massachusetts General Hospital | Nerve growth factor antibody and process |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| US5683894A (en) | 1988-04-29 | 1997-11-04 | University Of California | Recombinant nerve growth factor |
| US6440928B1 (en) | 1988-12-06 | 2002-08-27 | Colorado State University Research Foundation | Method for treating diabetic neuropathy with NGF |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5766883A (en) | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
| US6262239B1 (en) | 1989-05-18 | 2001-07-17 | Yeda Research And Development Co., Ltd. | TNF receptor-specific antibodies |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| US5656435A (en) | 1989-08-28 | 1997-08-12 | Takeda Chemical Industries, Ltd. | Antibodies to peptides having NGF-like activity, said antibodies having no substantial cross-reactivity with NGF, and use thereof |
| US5180820A (en) | 1989-08-30 | 1993-01-19 | Barde Yves Alain | Brain-derived neurotrophic factor |
| US5977307A (en) | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
| US5672683A (en) | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| US6566091B1 (en) | 1990-09-25 | 2003-05-20 | Genentech, Inc. | Neurotrophic factor |
| US6506728B2 (en) | 1990-09-25 | 2003-01-14 | Genentech, Inc. | Methods using a novel neurotrophic factor, NT-4 |
| US5604202A (en) | 1990-11-13 | 1997-02-18 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Use of NGF growth factors to treat drug-induced neuropathy |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US6140120A (en) | 1993-02-12 | 2000-10-31 | Board Of Trustees Of Leland Stanford Jr. University | Regulated transcription of targeted genes and other biological events |
| US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| AU6445894A (en) | 1993-03-19 | 1994-10-11 | Duke University | Method of treatment of tumors with an antibody binding to tenascin |
| ES2178654T3 (es) | 1993-08-12 | 2003-01-01 | Neurotech Sa | Capsulas biocompatibles inmonoaisladoras que contienen celulas geneticamente alteradas para el suministro de moleculas biologicamente activas. |
| US5908623A (en) | 1993-08-12 | 1999-06-01 | Cytotherapeutics, Inc. | Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules |
| US6562596B1 (en) | 1993-10-06 | 2003-05-13 | Amgen Inc. | Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5753225A (en) | 1993-12-03 | 1998-05-19 | The Regents Of The University Of California | Antibodies that mimic actions of neurotrophins |
| US6087171A (en) | 1993-12-17 | 2000-07-11 | Spinal Cord Society | Method for inducing DNA synthesis in neurons |
| GB9402331D0 (en) | 1994-02-07 | 1994-03-30 | Univ Mcgill | Nerve growth factor structural analogs and their uses |
| US6551618B2 (en) | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
| US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
| US5844092A (en) | 1994-03-18 | 1998-12-01 | Genentech, Inc. | Human TRK receptors and neurotrophic factor inhibitors |
| US6024734A (en) | 1994-03-31 | 2000-02-15 | Brewitt; Barbara A. | Treatment methods using homeopathic preparations of growth factors |
| US6291247B1 (en) | 1994-05-11 | 2001-09-18 | Queen's University At Kingston | Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity |
| US5728803A (en) | 1994-06-03 | 1998-03-17 | Genentech, Inc. | Pantropic neurotrophic factors |
| US7144983B1 (en) | 1997-02-03 | 2006-12-05 | Genentech, Inc. | Pantropic neurotrophic factors |
| US5840576A (en) | 1994-07-20 | 1998-11-24 | Cytotherapeutics, Inc. | Methods and compositions of growth control for cells encapsulated within bioartificial organs |
| AU3272695A (en) | 1994-08-12 | 1996-03-07 | Immunomedics Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
| US6271205B1 (en) | 1994-09-21 | 2001-08-07 | University Of Massachusetts Medical Center | Cancer treatment by expression of differentiation factor receptor |
| US5759775A (en) | 1994-10-27 | 1998-06-02 | Genetech, Inc. | Methods for detecting nucleic acids encoding AL--1 neurotrophic factor |
| US6096716A (en) | 1994-12-12 | 2000-08-01 | The Board Of Regents, The University Of Texas System | Liposome-mediated transfection of central nervous system cells |
| US6211142B1 (en) | 1995-03-10 | 2001-04-03 | Genentech, Inc. | Compositions comprising gas6 polypeptides and articles of manufacture comprising the same |
| US5688911A (en) | 1995-05-03 | 1997-11-18 | Schneider; Rainer | Trk neurotrophin binding motifs |
| US6717031B2 (en) | 1995-06-07 | 2004-04-06 | Kate Dora Games | Method for selecting a transgenic mouse model of alzheimer's disease |
| US5731284A (en) | 1995-09-28 | 1998-03-24 | Amgen Inc. | Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product |
| US20020090682A1 (en) | 1995-10-23 | 2002-07-11 | Tracy Willson | Novel haemopoietin receptor and genetic sequences encoding same |
| US6610296B2 (en) | 1995-10-26 | 2003-08-26 | Genentech, Inc. | Methods of enhancing cognitive function using an AL-1 neurotrophic factor immunoadhesin |
| GB9525180D0 (en) | 1995-12-08 | 1996-02-07 | Univ Mcgill | Design of hormone-like antibodies with agonistic and antagonistic fuctions |
| US6406710B1 (en) | 1996-01-16 | 2002-06-18 | Nikos Panayotatos | Protein occlusion for delivery of small molecules |
| JP2000507210A (ja) | 1996-01-16 | 2000-06-13 | パナヨタトス,ニコス | 小分子送達のためのタンパク質吸蔵 |
| US6299895B1 (en) | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
| GB9608335D0 (en) | 1996-04-23 | 1996-06-26 | Univ Kingston | Method of enhancing ngf-mediated neurite growth with low molecular weight analoues of p.75 ngfr 367-379 |
| US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
| US6391312B1 (en) | 1997-01-23 | 2002-05-21 | Sumitomo Pharmaceuticals Co., Limited | Remedies for diabetes |
| US6777196B2 (en) | 1997-02-18 | 2004-08-17 | Genentech, Inc. | Neurturin receptor |
| US6365373B2 (en) | 1997-04-25 | 2002-04-02 | Genentech, Inc. | Nucleic acids encoding NGF variants |
| US7452863B1 (en) | 1997-04-29 | 2008-11-18 | Genentech, Inc. | NGF variants |
| CA2294793A1 (fr) | 1997-06-30 | 1999-01-14 | Rhone-Poulenc Rorer S.A. | Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede |
| KR20010020570A (ko) | 1997-06-30 | 2001-03-15 | 자끄 사비나 | 다세포 진핵 생물 세포중으로 개선된 핵산 전달방법 및이를 위한 콤비네이션 |
| US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
| US5990129A (en) | 1997-09-23 | 1999-11-23 | Eli Lilly And Company | Methods for regulating trkA expression |
| US5968921A (en) | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
| US5928174A (en) | 1997-11-14 | 1999-07-27 | Acrymed | Wound dressing device |
| US7282482B2 (en) | 1998-04-08 | 2007-10-16 | The Regents Of The University Of California | NGF for the prevention of demyelination in the nervous system |
| US20030096753A1 (en) | 1998-04-09 | 2003-05-22 | Robertson Alan George Simpson | Therapeutic agent |
| GB9807781D0 (en) | 1998-04-09 | 1998-06-10 | Univ Bristol | Therapeutic agent |
| US6866842B1 (en) | 1998-05-01 | 2005-03-15 | University Of Pittsburgh | Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction |
| US6428579B1 (en) | 1998-07-01 | 2002-08-06 | Brown University Research Foundation | Implantable prosthetic devices coated with bioactive molecules |
| AU6151899A (en) | 1998-09-23 | 2000-04-10 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods of treating chronic pain |
| US6506599B1 (en) | 1999-10-15 | 2003-01-14 | Tai-Wook Yoon | Method for culturing langerhans islets and islet autotransplantation islet regeneration |
| US6680292B1 (en) | 1998-11-20 | 2004-01-20 | The Salk Institute For Biological Studies | Pharmaceutical composition comprising ribavirin and growth factors and methods of use |
| US6927024B2 (en) | 1998-11-30 | 2005-08-09 | Genentech, Inc. | PCR assay |
| US6652864B1 (en) | 1998-12-21 | 2003-11-25 | Asilomar Pharmaceuticals, Inc. | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
| RU2236251C2 (ru) | 1999-02-12 | 2004-09-20 | Дзе Скриппс Рисерч Инститьют | Способы лечения опухолей и метастазов с использованием комбинации антиангиогенной терапии и иммунотерапии |
| US6943153B1 (en) | 1999-03-15 | 2005-09-13 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| US8119101B2 (en) | 1999-05-10 | 2012-02-21 | The Ohio State University | Anti-CD74 immunoconjugates and methods of use |
| US7534866B2 (en) | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| US7550143B2 (en) | 2005-04-06 | 2009-06-23 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| US8383081B2 (en) | 1999-05-10 | 2013-02-26 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods of use |
| IT1306704B1 (it) | 1999-05-26 | 2001-10-02 | Sirs Societa Italiana Per La R | Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. |
| US20020177120A1 (en) | 1999-06-04 | 2002-11-28 | Kathryn J. Elliott | Assays for apotosis modulators |
| US20030152562A1 (en) | 2001-10-23 | 2003-08-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Vitro micro-organs, and uses related thereto |
| US8106098B2 (en) | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
| US6503713B1 (en) | 1999-10-04 | 2003-01-07 | University Of Medicine And Dentistry Of New Jersey | Methods for identifying RNA binding compounds |
| KR100416242B1 (ko) | 1999-12-22 | 2004-01-31 | 주식회사 삼양사 | 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법 |
| US6548062B2 (en) | 2000-02-29 | 2003-04-15 | Cephalon, Inc. | Method of treating cancer with anti-neurotrophin agents |
| PT2857516T (pt) | 2000-04-11 | 2017-08-28 | Genentech Inc | Anticorpos multivalentes e utilizações dos mesmos |
| FR2807660A1 (fr) | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
| US20040058393A1 (en) | 2000-04-17 | 2004-03-25 | Naoshi Fukishima | Agonist antibodies |
| US7473555B2 (en) | 2000-04-27 | 2009-01-06 | Geron Corporation | Protocols for making hepatocytes from embryonic stem cells |
| AU2001257532A1 (en) | 2000-05-03 | 2001-11-12 | University Of Washington | Adenoviral vectors for tumor specific gene expression and uses thereof |
| IL153375A0 (en) | 2000-06-22 | 2003-07-06 | Genentech Inc | Agonist anti-trk-c monoclonal antibodies |
| US6630490B2 (en) | 2000-07-07 | 2003-10-07 | Neotherapeutics, Inc. | Methods for treatment of disease-induced peripheral neuropathy and related conditions |
| US6719970B1 (en) | 2000-07-10 | 2004-04-13 | Alkermes Controlled Therapeutics, Inc. | Method of generating cartilage |
| US20020164333A1 (en) | 2000-07-10 | 2002-11-07 | The Scripps Research Institute | Bifunctional molecules and vectors complexed therewith for targeted gene delivery |
| AU2001276898A1 (en) | 2000-07-11 | 2002-01-21 | Binie V. Lipps | Synthetic peptide for neurological disorders |
| US20070122904A1 (en) | 2000-09-29 | 2007-05-31 | Unisearch Limited | Method and apparatus for culturing cells |
| CN1308447C (zh) | 2000-10-20 | 2007-04-04 | 中外制药株式会社 | 低分子化的激动剂抗体 |
| US20020128179A1 (en) | 2000-12-01 | 2002-09-12 | Tacon William C. | Shaped microparticles for pulmonary drug delivery |
| US20020115173A1 (en) | 2000-12-11 | 2002-08-22 | Children's Medical Center Corporation | Short peptides from the 'A-region' of protein kinases which selectively modulate protein kinase activity |
| US7169568B2 (en) | 2000-12-18 | 2007-01-30 | New York University | Method for screening molecules that exert a neurotrophic effect through activation of neurotrophin receptors |
| DE10101546B4 (de) | 2001-01-15 | 2005-04-28 | Man Technologie Gmbh | Verfahren zur Herstellung einer hochtemperaturfesten Faserverbundkeramik und so hergestellte Bauteile |
| US6602241B2 (en) | 2001-01-17 | 2003-08-05 | Transvascular, Inc. | Methods and apparatus for acute or chronic delivery of substances or apparatus to extravascular treatment sites |
| US20040115671A1 (en) | 2001-01-18 | 2004-06-17 | Zlokovic Berislav V | Gene expression profiling of endothelium in alzheimer's disease |
| US6551578B2 (en) | 2001-02-15 | 2003-04-22 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
| US6544497B2 (en) | 2001-02-15 | 2003-04-08 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
| US6485707B2 (en) | 2001-02-15 | 2002-11-26 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
| US6749845B2 (en) | 2001-02-15 | 2004-06-15 | Aeropharm Technology, Inc. | Modulated release particles for lung delivery |
| US6475468B2 (en) | 2001-02-15 | 2002-11-05 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
| US6596262B2 (en) | 2001-02-15 | 2003-07-22 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
| US7029916B2 (en) | 2001-02-21 | 2006-04-18 | Maxcyte, Inc. | Apparatus and method for flow electroporation of biological samples |
| CA2441588A1 (en) | 2001-03-23 | 2002-10-03 | Biopharm Gesellschaft Zue Biotechnologischen Entwicklung Von Pharmaka Mbh | Use of cytokines of the tgf-.beta. superfamily for the treatment and diagnosis of skin related disorders |
| CA2446886A1 (en) | 2001-04-06 | 2002-10-17 | Biovision Ag | Method for detecting chronic dementia diseases, and corresponding peptides and detection reagents |
| WO2002096356A2 (en) | 2001-05-25 | 2002-12-05 | Cornell Research Foundation, Inc. | HIGH AFFINITY LIGAND FOR p75 NEUROTROPHIN RECEPTOR |
| JP2002348234A (ja) | 2001-05-28 | 2002-12-04 | Purotekku:Kk | 薬物封入無機物微粒子、その製造法及び薬物封入無機物微粒子製剤 |
| KR20100132559A (ko) | 2001-05-30 | 2010-12-17 | 제넨테크, 인크. | 다양한 질환의 치료에 유용한 항-엔지에프 항체 |
| US20030008807A1 (en) | 2001-06-14 | 2003-01-09 | The Regents Of The University Of California | Novel signaling pathway for the production of inflammatory pain and neuropathy |
| WO2003015698A2 (en) | 2001-08-13 | 2003-02-27 | University Of Pittsburgh | Application of lipid vehicles and use for drug delivery |
| DK2574662T3 (da) | 2001-08-22 | 2021-09-20 | Maxcyte Inc | Fremgangsmåde til elektroporation af biologiske prøver |
| AU2002350352A1 (en) | 2001-12-21 | 2003-07-15 | Mount Sinai Hospital | Cellular compositions and methods of making and using them |
| US20050142539A1 (en) | 2002-01-14 | 2005-06-30 | William Herman | Targeted ligands |
| US20050069549A1 (en) | 2002-01-14 | 2005-03-31 | William Herman | Targeted ligands |
| IL152904A0 (en) | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
| CA2369810C (en) | 2002-01-30 | 2007-08-07 | 1474791 Ontario Limited | Method of treating pain |
| WO2003066821A2 (en) | 2002-02-04 | 2003-08-14 | The Johns Hopkins University | Molecules interacting with casl (mical) polynucleotides, polypeptides, and methods of using the same |
| US8491896B2 (en) | 2002-06-14 | 2013-07-23 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
| WO2003072753A2 (en) | 2002-02-27 | 2003-09-04 | Emory University | Multimeric binding complexes |
| JP2005520511A (ja) | 2002-03-18 | 2005-07-14 | ガミダ セル リミテッド | エクスビボ拡大培養された幹細胞における分化を誘導する方法 |
| US20040009589A1 (en) | 2002-03-26 | 2004-01-15 | Shulamit Levenberg | Endothelial cells derived from human embryonic stem cells |
| US20060093589A1 (en) | 2004-02-19 | 2006-05-04 | Warrington Kenneth H | Vp2-modified raav vector compositions and uses therefor |
| SI1496944T1 (sl) | 2002-05-01 | 2009-02-28 | Univ Florida | Izboljšani sistemi ekspresije RAAV za genetsko modifikacijo specifičnih kapsidnih proteinov |
| US20030235580A1 (en) | 2002-06-24 | 2003-12-25 | Fen Zhang | Amniotic membrane mediated delivery of bioactive molecules |
| JP2005537244A (ja) | 2002-06-28 | 2005-12-08 | ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド | 療法化合物の粘膜搬送を増進させるための、上皮接合部接着分子の生理機能を調節する組成物および方法 |
| CN1678634A (zh) | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
| AU2003256613A1 (en) | 2002-07-19 | 2004-02-09 | Amgen Inc. | Protein conjugates with a water-soluble biocompatible, biogradable polymer |
| US8263375B2 (en) | 2002-12-20 | 2012-09-11 | Acea Biosciences | Dynamic monitoring of activation of G-protein coupled receptor (GPCR) and receptor tyrosine kinase (RTK) in living cells using real-time microelectronic cell sensing technology |
| US7745151B2 (en) | 2002-08-02 | 2010-06-29 | Children's Medical Center Corporation | Methods of determining binding between Nogo receptor and p75 neurotrophin receptor |
| US20050074865A1 (en) | 2002-08-27 | 2005-04-07 | Compound Therapeutics, Inc. | Adzymes and uses thereof |
| US6919426B2 (en) | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
| CN1717483A (zh) | 2002-10-04 | 2006-01-04 | 麒麟麦酒株式会社 | 人类人工染色体(hac)载体 |
| EP1545615A4 (en) | 2002-10-04 | 2006-03-01 | Rinat Neuroscience Corp | METHODS OF TREATING CARDIAC ARRHYTHMIA AND PREVENTING DEATH OF CARDIAC ARRHYTHMIA USING NGF ANTAGONISTS |
| WO2004032870A2 (en) * | 2002-10-08 | 2004-04-22 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same |
| US7255860B2 (en) | 2002-10-08 | 2007-08-14 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody |
| UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| MXPA05004202A (es) | 2002-10-22 | 2005-09-20 | Waratah Pharmaceuticals Inc | Tratamiento de la diabetes. |
| FR2846426B1 (fr) | 2002-10-28 | 2004-12-10 | Bio Merieux | Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie |
| US20050054097A1 (en) | 2002-11-17 | 2005-03-10 | Tony Peled | EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures |
| DK1891966T3 (da) | 2002-12-20 | 2012-04-02 | Lundbeck & Co As H | Modulation af neurotrophinaktivitet; fremgangsmåde til screening |
| US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
| DK1575517T3 (da) * | 2002-12-24 | 2012-05-14 | Rinat Neuroscience Corp | Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| US20060147932A1 (en) | 2003-01-18 | 2006-07-06 | Alun Davies | Methods of screening for modulators of nerve growth factor |
| WO2004065417A2 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| KR20050111598A (ko) | 2003-02-19 | 2005-11-25 | 리나트 뉴로사이언스 코퍼레이션 | 신경 성장 인자 길항제 및 nsaid를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물 |
| US8545830B2 (en) | 2003-03-24 | 2013-10-01 | University Of Tennessee Research Foundation | Multi-functional polymeric materials and their uses |
| US20060193825A1 (en) | 2003-04-29 | 2006-08-31 | Praecis Phamaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| JP2007504920A (ja) | 2003-05-16 | 2007-03-08 | ブルー メンブレーンス ゲーエムベーハー | 生体適合性コーティングされた医療用インプラント |
| JP2007501021A (ja) | 2003-05-30 | 2007-01-25 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 遺伝子操作された定常領域を含む、抗体および融合タンパク質 |
| US20070020696A1 (en) | 2003-07-10 | 2007-01-25 | Marino Zerial | Appl proteins as rab5 effectors |
| UA97086C2 (uk) | 2003-07-15 | 2012-01-10 | Емджен, Інк. | Виділене людське антитіло, яке специфічно зв'язується з фактором росту нервової тканини (ngf) |
| US20050027110A1 (en) | 2003-07-24 | 2005-02-03 | Michael Russell | Drug delivery in the nervous system |
| EP1500399A1 (en) | 2003-07-24 | 2005-01-26 | Institut Pasteur | Active or passive immunization against proapoptotic neurotrophins for the treatment or prevention of neurodegenerative deseases |
| US7205387B2 (en) | 2003-08-28 | 2007-04-17 | Agency For Science, Technology And Research | Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist |
| US20050085417A1 (en) | 2003-10-16 | 2005-04-21 | Thomas Jefferson University | Compounds and methods for diagnostic imaging and therapy |
| US7846891B2 (en) | 2003-10-17 | 2010-12-07 | Massachusetts Institute Of Technology | Self-assembling peptides for regeneration and repair of neural tissue |
| DK1678314T3 (da) | 2003-10-22 | 2012-12-03 | Keck Graduate Inst | Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi |
| US8133733B2 (en) | 2003-10-24 | 2012-03-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to target tissues |
| US20090123468A1 (en) | 2003-10-24 | 2009-05-14 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
| WO2005051423A2 (en) | 2003-11-30 | 2005-06-09 | Yeda Research And Development Co. Ltd | Methods and agents for immune modulation and methods for identifying immune modulators |
| US8093205B2 (en) | 2003-12-01 | 2012-01-10 | Medtronic, Inc. | Method for treating a stroke by implanting a first therapy delivery element in the CNS and a second therapy delivery element in a damaged tissue of the CNS to promote neurogenesis |
| US20050123526A1 (en) | 2003-12-01 | 2005-06-09 | Medtronic Inc. | Administration of growth factors for neurogenesis and gliagenesis |
| CA2549000A1 (en) | 2003-12-16 | 2005-06-30 | Children's Medical Center Corporation | Method for treating neurological disorders |
| PT1718677E (pt) | 2003-12-19 | 2012-07-18 | Genentech Inc | Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos |
| DE10360483B4 (de) | 2003-12-22 | 2007-11-15 | Scil Proteins Gmbh | Expressionsvektor und dessen Verwendung |
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| WO2005065721A2 (en) | 2003-12-30 | 2005-07-21 | Board Of Regents, The University Of Texas System | Use of an anti-inflammatory compound for the reduction of inflammation secondary to the administration of a lipid-nucleic acid complex |
| US20110171126A1 (en) | 2010-01-11 | 2011-07-14 | Center For Molecular Medicine And Immunology | Enhanced Cytotoxicity of Anti-CD74 and Anti-HLA-DR Antibodies with Interferon-Gamma |
| US8562988B2 (en) | 2005-10-19 | 2013-10-22 | Ibc Pharmaceuticals, Inc. | Strategies for improved cancer vaccines |
| US8883160B2 (en) | 2004-02-13 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
| US20050260711A1 (en) | 2004-03-30 | 2005-11-24 | Deepshikha Datta | Modulating pH-sensitive binding using non-natural amino acids |
| KR101637908B1 (ko) | 2004-04-07 | 2016-07-11 | 리나트 뉴로사이언스 코프. | 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법 |
| WO2005100589A2 (en) | 2004-04-19 | 2005-10-27 | Hankins William D | Kinetic process for the detection, diagnosis, processing, and monitoring of clonal cell populations |
| ITRM20040212A1 (it) | 2004-04-30 | 2004-07-30 | Lay Line Genomics Spa | Animale transgenico non umano come modello per malattie neurodegenerative e per la loro diagnosi precoce. |
| AU2005249396B2 (en) | 2004-05-05 | 2011-10-20 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
| US8921528B2 (en) | 2004-06-01 | 2014-12-30 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
| WO2005120519A1 (en) | 2004-06-10 | 2005-12-22 | The Walter And Eliza Hall Institute Of Medical Research | Glycosylphosphatidylinositol glycan signalling via integrins functioning as glycan specific receptors |
| US7740861B2 (en) | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
| AU2005257064B2 (en) | 2004-06-28 | 2012-05-10 | Yeda Research And Development Co. Ltd. | Chimeric proteins and uses thereof |
| US7514088B2 (en) | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| ME00226B (me) | 2004-07-15 | 2011-02-10 | Medarex Llc | Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade |
| EP1778856A4 (en) | 2004-08-02 | 2008-05-28 | Childrens Medical Center | BLOOD BIOMARKER FOR CANCER |
| ME01803B (me) | 2004-08-05 | 2010-12-31 | Genentech Inc | Humanizovani anti-cmet antagonisti |
| KR100876771B1 (ko) | 2004-08-17 | 2009-01-07 | 삼성전자주식회사 | 무선 통신 시스템에서 제어 정보 압축 방법과 스캐닝 정보 송수신 방법 및 장치 |
| US20060068469A1 (en) | 2004-08-17 | 2006-03-30 | Research Development Foundation | Bacterial vector systems |
| EP1982997B1 (en) | 2004-09-01 | 2012-08-08 | Allergan, Inc. | Degradable clostridial toxins |
| AU2005284835A1 (en) | 2004-09-14 | 2006-03-23 | Novartis Vaccines And Diagnostics Inc. | Imidazoquinoline compounds |
| CA2580796C (en) | 2004-09-24 | 2013-03-26 | Amgen Inc. | Modified fc molecules having peptides inserted in internal loop regions |
| US7629325B2 (en) | 2004-10-11 | 2009-12-08 | Technion Research & Development Foundation Ltd. | Human Sef isoforms and methods of using same for cancer diagnosis and gene therapy |
| BRPI0516992A8 (pt) | 2004-10-22 | 2018-04-03 | Univ South Florida | Método de potencializar modulação imune e inflamatória para célula e terapia de droga |
| US7671057B2 (en) | 2004-11-08 | 2010-03-02 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for type II diabetes comprising protease-inhibiting compound |
| WO2006055841A2 (en) | 2004-11-19 | 2006-05-26 | University Of Florida Research Foundation, Inc. | Indefinite culture of human adult glia without immortalization and therapeutic uses thereof |
| WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| JP5096167B2 (ja) * | 2005-01-24 | 2012-12-12 | メドイミューン リミテッド | Ngfに対する特異的結合メンバー |
| ES2428869T3 (es) | 2005-01-24 | 2013-11-12 | Pepscan Systems B.V. | Compuestos de unión, compuestos inmunógenos y peptidomiméticos |
| CA2595695A1 (en) | 2005-01-25 | 2006-08-03 | Cell Therapeutics, Inc. | Biologically active protein conjugates comprising (nn[s/t]) peptide repeats and having increased plasma half-life |
| WO2006084173A1 (en) | 2005-02-04 | 2006-08-10 | The Johns Hopkins University | Electroporation gene therapy gun system |
| US20060182724A1 (en) | 2005-02-15 | 2006-08-17 | Riordan Neil H | Method for expansion of stem cells |
| WO2006101634A1 (en) | 2005-02-17 | 2006-09-28 | The Regents Of The University Of California | Müller cell specific gene therapy |
| US20090136505A1 (en) | 2005-02-23 | 2009-05-28 | Johanna Bentz | Intranasal Administration of Active Agents to the Central Nervous System |
| CN101171034B (zh) | 2005-03-03 | 2014-06-18 | 免疫医疗公司 | 人源化l243抗体 |
| US8658778B2 (en) | 2005-03-09 | 2014-02-25 | Board Of Regents, The University Of Texas System | hTMC promoter and vectors for the tumor-selective and high-efficient expression of cancer therapeutic genes |
| CA2602951A1 (en) | 2005-03-23 | 2006-09-28 | Bio-Rad Laboratories, Inc. | Diverse chemical libraries bound to small particles with paramagnetic properties |
| US8349332B2 (en) | 2005-04-06 | 2013-01-08 | Ibc Pharmaceuticals, Inc. | Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases |
| CA2607475A1 (en) | 2005-04-22 | 2006-11-02 | Genentech, Inc. | Method for treating dementia or alzheimer's disease with a cd20 antibody |
| RU2007146986A (ru) | 2005-06-02 | 2009-06-27 | ГЭЛЭКСИ БАЙОТЕК, ЭлЭлСи (US) | Способы лечения опухолей головного мозга с использованием антител |
| MX2007015292A (es) | 2005-06-06 | 2008-02-21 | Wyeth Corp | Anticuerpos monoclonales anti-trkb y sus usos. |
| ITRM20050290A1 (it) * | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| DE602005012812D1 (de) | 2005-06-13 | 2009-04-02 | Primm Srl | Heterodimere Peptide mit NGF Aktivität und deren Verwendung zur Behandlung von neurodegenerativen Krankheiten |
| JP2008543839A (ja) | 2005-06-14 | 2008-12-04 | アムジェン インコーポレーテッド | 自己緩衝タンパク質製剤 |
| US8877714B2 (en) | 2005-06-14 | 2014-11-04 | Raptor Pharmaceutical Inc. | Compositions comprising receptor-associated protein (RAP) variants specific for LRP2 and uses thereof |
| ITRM20050332A1 (it) | 2005-06-24 | 2006-12-25 | Lay Line Genomics Spa | Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore. |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| WO2007019620A1 (en) | 2005-08-15 | 2007-02-22 | Arana Therapeutics Limited | Engineered antibodies with new world primate framework regions |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| WO2007025166A2 (en) | 2005-08-25 | 2007-03-01 | Repair Technologies, Inc. | Devices, compositions and methods for the protection and repair of cells and tissues |
| CA2623648C (en) | 2005-09-21 | 2018-05-22 | The Regents Of The University Of California | Systems, compositions, and methods for local imaging and treatment of pain |
| US8053569B2 (en) | 2005-10-07 | 2011-11-08 | Armagen Technologies, Inc. | Nucleic acids encoding and methods of producing fusion proteins |
| WO2007051477A2 (en) | 2005-11-07 | 2007-05-10 | Copenhagen University | Neurotrophin-derived peptide sequences |
| CN101573441A (zh) | 2005-12-08 | 2009-11-04 | 路易斯维尔大学研究基金会有限公司 | 非常小的胚胎样(vsel)干细胞及分离和利用其的方法 |
| US20070243132A1 (en) | 2005-12-22 | 2007-10-18 | Apollo Life Sciences Limited | Transdermal delivery of pharmaceutical agents |
| EP1971288B1 (en) | 2005-12-30 | 2013-02-13 | Neurotech USA, Inc. | Micronized device for the delivery of biologically active molecules and methods of use thereof |
| US7342146B2 (en) | 2006-01-11 | 2008-03-11 | Industrial Technology Research Institute | Neurodegenerative non-human transgenic mammal expressing TrkA fusion protein |
| KR100784485B1 (ko) | 2006-01-18 | 2007-12-11 | 한국과학기술연구원 | 생분해성 온도 감응성 폴리포스파젠계 하이드로젤, 그의제조방법 및 그의 용도 |
| US20070213822A1 (en) | 2006-02-14 | 2007-09-13 | Sdgi Holdings, Inc. | Treatment of the vertebral column |
| SI1988910T1 (en) | 2006-02-28 | 2018-02-28 | Kodiak Sciences Inc. | Polymeric conjugates containing acryloyloxyethylphosphorylcholine and their preparations |
| CA2647632C (en) | 2006-03-27 | 2017-06-27 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| KR100746962B1 (ko) | 2006-04-04 | 2007-08-07 | 한국과학기술연구원 | 온도 감응성 포스파젠계 고분자-생리 활성 물질 복합체,그의 제조방법 및 그의 용도 |
| SI2019683T2 (sl) | 2006-04-25 | 2022-10-28 | The Regents Of The University Of California | Dajanje rastnih faktorjev za zdravljenje motenj CŽS |
| CN101506358B (zh) | 2006-05-15 | 2013-07-17 | 免疫医学股份有限公司 | 使用偶合的抗体或抗体片段治疗人免疫缺陷病毒感染的方法和组合物 |
| EP2021463B1 (en) | 2006-05-19 | 2016-11-23 | Alder Biopharmaceuticals, Inc. | Culture method for obtaining a clonal population of antigen-specific b cells |
| US8623610B2 (en) | 2006-05-22 | 2014-01-07 | California Institute Of Technology | Chondroitin sulfate binding proteins and modulators thereof |
| EP2029726A4 (en) | 2006-06-09 | 2010-07-28 | Univ Miami | ASSESSMENT OF CELL COMPOSITION AND FRACTIVITY AND USES THEREOF |
| US8475788B2 (en) | 2006-06-14 | 2013-07-02 | Stemnion, Inc. | Methods of treating spinal cord injury and minimizing scarring |
| TW200817512A (en) | 2006-07-07 | 2008-04-16 | Kirin Pharma Kk | Human artificial chromosome (hac) vector, and human cell pharmaceutical comprising human artificial chromosome (hac) vector |
| WO2008011567A2 (en) | 2006-07-21 | 2008-01-24 | Amgen, Inc. | Cell systems and methods for detecting proliferation activity |
| EP1882697B1 (en) | 2006-07-24 | 2010-04-21 | Institut Pasteur | Antibodies, antibody fragments and scFv binding to post-translationally modified neurotrophins |
| EP2068866A4 (en) | 2006-07-24 | 2010-04-07 | Biogen Idec Inc | METHODS FOR PROMOTING MYELINIZATION, NEURONAL SURVIVAL AND DIFFERENTIATION OF OLIGODENDROCYTES BY ADMINISTERING SP35 OR TRKA ANTAGONISTS |
| US8168169B2 (en) | 2006-08-09 | 2012-05-01 | Mclean Hospital Corporation | Methods and compositions for the treatment of medical disorders |
| WO2008024499A2 (en) | 2006-08-25 | 2008-02-28 | Duke University | Methods for in vivo identification of endogenous mrna targets of micrornas |
| US20090004742A1 (en) | 2006-11-01 | 2009-01-01 | Duke University | Selection of antigen-specific t cells |
| GB0622688D0 (en) | 2006-11-14 | 2006-12-27 | Diosamine Dev Corp | Novel compounds |
| US8648169B2 (en) | 2006-12-05 | 2014-02-11 | The Royal Institution For The Advancement Of Learning/Mcgill University | Methods of use of Trk receptor modulators |
| US20080139790A1 (en) | 2006-12-08 | 2008-06-12 | Jennings Philip A | Chimeric antibodies |
| PL3225251T3 (pl) | 2006-12-21 | 2020-06-29 | H. Lundbeck A/S | Modulacja aktywności proneurotrofin |
| AU2007336770A1 (en) | 2006-12-22 | 2008-07-03 | Genentech, Inc. | DR6 antibodies inhibiting the binding of DR6 to APP, and uses thereof in treating neurological disorders |
| US8183219B2 (en) | 2007-01-03 | 2012-05-22 | Medtronic, Inc. | Therapeuting compositions comprising an RNAi agent and a neurotrophic factor and methods of use thereof |
| WO2008089148A1 (en) | 2007-01-12 | 2008-07-24 | Biomarin Pharmaceutical Inc. | Method of treating a metabolic or neuropsychiatry disorder with a bh4 derivative prodrug |
| US8057798B2 (en) | 2007-02-02 | 2011-11-15 | Baylor Research Institute | Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells |
| EP2684889A3 (en) | 2007-02-02 | 2014-03-05 | Baylor Research Institute | Multivariable antigens complexed with targeting humanized monoclonal antibody |
| US20080233088A1 (en) | 2007-02-16 | 2008-09-25 | Varian Medical Systems Technologies, Inc. | Preparative regimen for engraftment, growth and differentiation of non-hematopoeitic cells in vivo after transplantation |
| JP5675109B2 (ja) | 2007-02-20 | 2015-02-25 | アナプティスバイオ インコーポレイティッド | ライブラリーの生成方法及びその使用 |
| CA2717656A1 (en) | 2007-02-23 | 2008-08-28 | Baylor Research Institute | Activation of human antigen-presenting cells through clec-6 |
| TWI423985B (zh) | 2007-02-23 | 2014-01-21 | 貝勒研究協會 | 利用dectin-1活化人類抗原呈現細胞之醫療應用 |
| US20110268776A1 (en) | 2007-04-25 | 2011-11-03 | Schapira Jay N | Programmed-release, nanostructured biological construct for stimulating cellular engraftment for tissue regeneration |
| DK2164514T3 (en) | 2007-05-21 | 2017-02-27 | Alderbio Holdings Llc | Antibodies to IL-6 and its use |
| WO2008144753A2 (en) | 2007-05-21 | 2008-11-27 | Alder Biopharmaceuticals, Inc. | Antibodies to tnf alpha and use thereof |
| NZ601583A (en) | 2007-05-21 | 2013-08-30 | Bristol Myers Squibb Co | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| MX2009012609A (es) | 2007-05-22 | 2009-12-07 | Amgen Inc | Composiciones y metodos para producir proteinas de fusion bioactivas. |
| US20090232801A1 (en) | 2007-05-30 | 2009-09-17 | Abbot Laboratories | Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof |
| PE20090329A1 (es) | 2007-05-30 | 2009-03-27 | Abbott Lab | Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos |
| AU2008255352B2 (en) | 2007-05-31 | 2014-05-22 | Genmab A/S | Stable IgG4 antibodies |
| KR100968591B1 (ko) | 2007-06-14 | 2010-07-08 | 한국과학기술연구원 | 약물전달용 폴리포스파젠계 하이드로젤, 그의 제조방법 및그의 용도 |
| US20080318314A1 (en) | 2007-06-20 | 2008-12-25 | Valentin Fulga | Production from blood of cells of neural lineage |
| WO2009003145A1 (en) | 2007-06-26 | 2008-12-31 | University Of Miami | Antibody-endostatin fusion protein and its variants |
| EP2586788B1 (en) | 2007-07-09 | 2017-11-29 | Genentech, Inc. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
| PL2187964T3 (pl) * | 2007-08-10 | 2015-03-31 | Regeneron Pharma | Ludzkie przeciwciała o wysokim powinowactwie przeciw ludzkiemu czynnikowi wzrostu nerwu |
| US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| WO2009032148A1 (en) | 2007-08-29 | 2009-03-12 | Tufts University | Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits |
| EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
| US20110034383A1 (en) | 2007-10-15 | 2011-02-10 | Institut Pasteur | Cxcl12 gamma a chemokine and uses thereof |
| WO2009062151A1 (en) | 2007-11-08 | 2009-05-14 | Cytimmune Sciences, Inc. | Compositions and methods for generating antibodies |
| EP2220125A4 (en) | 2007-11-13 | 2010-12-29 | Sapphire Energy Inc | PRODUCTION OF FC HYBRID POLYPEPTIDES IN EUKARYOTIC ALGAE |
| EP2220115A2 (en) | 2007-12-13 | 2010-08-25 | Glaxo Group Limited | Polypeptides, antibody variable domains & antagonists |
| JP5737944B2 (ja) | 2007-12-17 | 2015-06-17 | ファイザー・リミテッドPfizer Limited | 間質性膀胱炎の治療 |
| EA021967B1 (ru) | 2008-01-03 | 2015-10-30 | Дзе Скриппс Рисерч Инститьют | Доставка антител посредством модульного домена распознавания |
| US8426673B2 (en) | 2008-01-11 | 2013-04-23 | Astellas Pharma, Inc. | Pathological animal model for pelvic pain syndrome |
| EP2249856B1 (en) | 2008-01-30 | 2013-11-06 | Baylor College Of Medicine | Peptides that target dorsal root ganglion neurons |
| BRPI0905955A8 (pt) | 2008-02-04 | 2018-05-08 | Lay Line Genomics Spa | anticorpo ani trka, anticorpo ou derivado, derivado de um anticorpo, combinação de um anticorpo ou derivado, composição farmaceutica, método, polipetídeo, ácido nucléico codificante de um aniticorpo ou derivado do mesmo, vetor, sistema de expressão ,mamífero transgênico não humano e kit compreendo um anticorpo ou derivado |
| US8236527B2 (en) | 2008-03-14 | 2012-08-07 | Humanzyme Limited | Recombinant production of authentic human proteins using human cell expression systems |
| EP2254886B1 (en) | 2008-03-28 | 2016-05-25 | Nerviano Medical Sciences S.r.l. | 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| WO2009132656A2 (en) | 2008-04-27 | 2009-11-05 | H. Lundbeck A/S | Design of specific ligands to sortilin |
| EP2297209A4 (en) | 2008-06-03 | 2012-08-01 | Abbott Lab | IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF |
| KR20110016959A (ko) | 2008-06-03 | 2011-02-18 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| WO2009150623A1 (en) | 2008-06-13 | 2009-12-17 | Pfizer Inc | Treatment of chronic prostatitis |
| ES2464459T3 (es) | 2008-06-25 | 2014-06-02 | H. Lundbeck A/S | Modulación del sistema receptor Trpv:receptor de dominio Vps 10p para el tratamiento del dolor |
| US8822645B2 (en) | 2008-07-08 | 2014-09-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
| CN101633694B (zh) | 2008-07-24 | 2012-08-29 | 厦门北大之路生物工程有限公司 | 抗鼠神经生长因子(ngf)的多克隆抗体的制备方法及其应用 |
| WO2010022225A1 (en) | 2008-08-20 | 2010-02-25 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (dnl) vaccines for cancer therapy |
| SI2331090T1 (en) | 2008-09-19 | 2018-04-30 | Pfizer Inc. | Stable liquid antibody formulation |
| WO2010036443A1 (en) | 2008-09-26 | 2010-04-01 | Eureka Therapeutics, Inc. | Cell lines and proteins with variant glycosylation pattern |
| JP5879126B2 (ja) | 2008-10-07 | 2016-03-08 | ジン・トゥオJIN Tuo | 相転移ポリマーマイクロニードル |
| CA2741089A1 (en) | 2008-10-22 | 2010-04-29 | Genentech, Inc. | Modulation of axon degeneration |
| US20100104652A1 (en) | 2008-10-27 | 2010-04-29 | University Of Arkansas | Use of advanced nanomaterials for increasing sepecific cell functions |
| WO2010051032A1 (en) | 2008-10-31 | 2010-05-06 | Synthes Usa, Llc | Method and device for activating stem cells |
| CA2745439C (en) | 2008-12-03 | 2019-10-15 | Genmab A/S | Antibody variants having modifications in the constant region |
| FR2944448B1 (fr) | 2008-12-23 | 2012-01-13 | Adocia | Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes. |
| CA2745903C (en) | 2008-12-31 | 2018-07-17 | Kci Licensing, Inc. | System for providing fluid flow to nerve tissues |
| CA2750027C (en) | 2009-01-23 | 2020-11-10 | Nsgene A/S | Improved cell lines and their use in encapsulated cell biodelivery |
| ES2514319T3 (es) | 2009-05-04 | 2014-10-28 | Abbvie Research B.V. | Anticuerpos contra el factor de crecimiento nervioso (NGF) con estabilidad in vivo mejorada |
| SG177288A1 (en) | 2009-07-02 | 2012-02-28 | Glaxo Group Ltd | Polypeptides and method of treatment |
| US20110033463A1 (en) | 2009-08-06 | 2011-02-10 | Medtronic, Inc. | Apheresis, administration of agent, or combination thereof |
| MX355650B (es) | 2009-08-11 | 2018-04-26 | Genentech Inc | Produccion de proteinas en medios de cultivo de celulas libres de glutamina. |
| JO3246B1 (ar) | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
| WO2011034660A1 (en) | 2009-09-16 | 2011-03-24 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
| US9155722B2 (en) | 2009-09-18 | 2015-10-13 | Protherics Salt Lake City, Inc. | Reconstitutable reverse thermal gelling polymers |
| US8753621B2 (en) | 2009-09-18 | 2014-06-17 | Protherics Salt Lake City, Inc. | BAB triblock polymers having improved release characteristics |
| AR078651A1 (es) | 2009-10-15 | 2011-11-23 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| EP2528649A1 (en) | 2010-01-26 | 2012-12-05 | Michael A. Evans | Methods, devices, and agents for denervation |
| WO2011100636A1 (en) | 2010-02-11 | 2011-08-18 | The Board Of Trustees Of The Leland Stanford Junior University | Markers for determination of patient responsiveness |
| KR20130031247A (ko) | 2010-03-17 | 2013-03-28 | 애보트 리서치 비.브이. | 항―신경 성장 인자(ngf) 항체 조성물 |
| EP2552483A4 (en) | 2010-04-01 | 2013-09-25 | Immunomedics Inc | USE OF ANTIBODIES TO REDUCE THE NUMBER OF CELLS CONTAINING ANTIGENS AND DENDRITIC CELLS |
| MX2012011629A (es) | 2010-04-07 | 2013-03-05 | Abbvie Inc | Proteinas de union a tnf-alfa. |
| NZ602618A (en) | 2010-04-12 | 2013-12-20 | Somalogic Inc | Aptamers to beta-ngf and their use in treating beta-ngf mediated diseases and disorders |
| UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| JOP20190250A1 (ar) | 2010-07-14 | 2017-06-16 | Regeneron Pharma | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب |
| ES2665954T3 (es) | 2010-08-19 | 2018-04-30 | Zoetis Belgium S.A. | Anticuerpos anti-NGF y su uso |
| US9046513B2 (en) | 2010-08-26 | 2015-06-02 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US9783601B2 (en) | 2010-12-01 | 2017-10-10 | Alderbio Holdings Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US20120195900A1 (en) | 2010-12-22 | 2012-08-02 | Abbott Laboratories | Tri-variable domain binding proteins and uses thereof |
| US20120201746A1 (en) | 2010-12-22 | 2012-08-09 | Abbott Laboratories | Half immunoglobulin binding proteins and uses thereof |
| US8668886B2 (en) | 2011-04-24 | 2014-03-11 | Therapeutic Proteins International, LLC | Separative bioreactor |
| SG10201500957QA (en) | 2011-05-06 | 2015-04-29 | Nvip Pty Ltd | Anti-nerve growth factor antibodies and methods of preparing and using the same |
| AU2012252152B2 (en) | 2011-05-06 | 2016-07-07 | Zoetis Services Llc | Anti-nerve growth factor antibodies and methods of preparing and using the same |
| CA2842492A1 (en) | 2011-08-05 | 2013-02-14 | Bioasis Technologies, Inc. | P97 fragments with transfer activity |
| RS56876B1 (sr) | 2011-08-11 | 2018-04-30 | Astellas Pharma Inc | Novo antitelo protiv humanog ngf |
| US8926978B2 (en) | 2011-10-25 | 2015-01-06 | Anaptysbio, Inc. | Antibodies directed against nerve growth factor (NGF) |
| UA113879C2 (xx) | 2012-06-08 | 2017-03-27 | ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ | |
| EP2674439B1 (en) | 2012-06-13 | 2017-02-01 | Rottapharm Biotech S.r.l. | Anti-TrkA antibodies, derivatives and uses thereof |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
-
2011
- 2011-12-01 US US13/308,831 patent/US9783601B2/en not_active Expired - Fee Related
- 2011-12-01 AU AU2011336470A patent/AU2011336470B8/en not_active Ceased
- 2011-12-01 KR KR1020137017181A patent/KR102025848B1/ko not_active Expired - Fee Related
- 2011-12-01 CN CN201180066555.0A patent/CN103619879A/zh active Pending
- 2011-12-01 US US13/309,295 patent/US9783602B2/en not_active Expired - Fee Related
- 2011-12-01 CA CA2821515A patent/CA2821515A1/en not_active Abandoned
- 2011-12-01 JP JP2013542189A patent/JP6190723B2/ja not_active Expired - Fee Related
- 2011-12-01 WO PCT/US2011/062963 patent/WO2012075340A2/en not_active Ceased
- 2011-12-01 US US13/308,665 patent/US8911734B2/en not_active Expired - Fee Related
- 2011-12-01 EP EP11844615.2A patent/EP2646468B1/en not_active Not-in-force
- 2011-12-01 KR KR1020197027515A patent/KR20190112175A/ko not_active Ceased
- 2011-12-01 EP EP18176490.3A patent/EP3434691A1/en not_active Withdrawn
- 2011-12-01 MX MX2013006125A patent/MX359070B/es active IP Right Grant
- 2011-12-01 NZ NZ611076A patent/NZ611076A/en not_active IP Right Cessation
- 2011-12-01 US US13/309,153 patent/US8728473B2/en not_active Expired - Fee Related
-
2014
- 2014-11-05 US US14/533,645 patent/US9359432B2/en not_active Expired - Fee Related
-
2016
- 2016-10-14 US US15/294,016 patent/US10344083B2/en not_active Expired - Fee Related
- 2016-12-26 JP JP2016251053A patent/JP2017079779A/ja not_active Abandoned
-
2017
- 2017-07-28 AU AU2017208339A patent/AU2017208339A1/en not_active Abandoned
-
2019
- 2019-07-08 US US16/504,602 patent/US20200062837A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017079779A (ja) | 抗ngf組成物およびその使用 | |
| JP6754456B2 (ja) | 羞明または光嫌悪症を予防または抑制する抗cgrp抗体および抗体断片のそれを必要とする対象、特に片頭痛患者における使用 | |
| JP6189832B2 (ja) | 慢性および急性の下痢を治療または予防するための抗cgrp若しくは抗cgrp−rの抗体または抗体断片の使用 | |
| US9884909B2 (en) | Anti-NGF compositions and use thereof | |
| US20200062838A1 (en) | Methods of preventing inflammation and treating pain using anti-ngf compositions | |
| US10227402B2 (en) | Anti-NGF antibodies and anti-NGF antibody fragments | |
| US10221236B2 (en) | Anti-NGF antibodies that selectively inhibit the association of NGF with TRKA without affecting the association of NGF with P75 | |
| EA047357B1 (ru) | Применение антител или фрагментов антител против cgrp или против cgrp-r для лечения или профилактики хронических и острых форм диареи | |
| EA046371B1 (ru) | Применение антител и фрагментов антител против cgrp для профилактики или ингибирования светобоязни или отвращения к свету у субъектов, нуждающихся в этом, в особенности страдающих мигренью |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141201 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141201 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151119 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160218 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160322 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160419 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160519 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160823 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161226 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20170106 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170308 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170515 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170616 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170619 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170707 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170807 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6190723 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |